These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 20124001)

  • 21. Role of Rilpivirine and Etravirine in Efavirenz and Nevirapine-Based Regimens Failure in a Resource-Limited Country: A Cross- Sectional Study.
    Teeranaipong P; Sirivichayakul S; Mekprasan S; Ohata PJ; Avihingsanon A; Ruxrungtham K; Putcharoen O
    PLoS One; 2016; 11(4):e0154221. PubMed ID: 27120449
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Genetic divergence of human immunodeficiency virus type 1 Ethiopian clade C reverse transcriptase (RT) and rapid development of resistance against nonnucleoside inhibitors of RT.
    Loemba H; Brenner B; Parniak MA; Ma'ayan S; Spira B; Moisi D; Oliveira M; Detorio M; Wainberg MA
    Antimicrob Agents Chemother; 2002 Jul; 46(7):2087-94. PubMed ID: 12069959
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Patients infected with HIV type 1 subtype CRF01_AE and failing first-line nevirapine- and efavirenz-based regimens demonstrate considerable cross-resistance to etravirine.
    Manosuthi W; Butler DM; Chantratita W; Sukasem C; Richman DD; Smith DM
    AIDS Res Hum Retroviruses; 2010 Jun; 26(6):609-11. PubMed ID: 20507208
    [No Abstract]   [Full Text] [Related]  

  • 24. Resistance patterns selected by nevirapine vs. efavirenz in HIV-infected patients failing first-line antiretroviral treatment: a bayesian analysis.
    Ngo-Giang-Huong N; Jourdain G; Amzal B; Sang-a-gad P; Lertkoonalak R; Eiamsirikit N; Tansuphasawasdikul S; Buranawanitchakorn Y; Yutthakasemsunt N; Mekviwattanawong S; McIntosh K; Lallemant M;
    PLoS One; 2011; 6(11):e27427. PubMed ID: 22132100
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prevalence of etravirine-associated mutations in clinical samples with genotypic resistance to nevirapine and efavirenz in Brazilian clinics.
    Martins AN; Arruda MB; Aleixo AW; Pires AF; Greco DB; de M Brindeiro R; Tanuri A
    J Acquir Immune Defic Syndr; 2011 Aug; 57 Suppl 3():S193-6. PubMed ID: 21857317
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Human immunodeficiency virus type 1 resistance or cross-resistance to nonnucleoside reverse transcriptase inhibitors currently under development as microbicides.
    Selhorst P; Vazquez AC; Terrazas-Aranda K; Michiels J; Vereecken K; Heyndrickx L; Weber J; Quiñones-Mateu ME; Ariën KK; Vanham G
    Antimicrob Agents Chemother; 2011 Apr; 55(4):1403-13. PubMed ID: 21282453
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The connection domain mutation N348I in HIV-1 reverse transcriptase enhances resistance to etravirine and rilpivirine but restricts the emergence of the E138K resistance mutation by diminishing viral replication capacity.
    Xu HT; Colby-Germinario SP; Oliveira M; Han Y; Quan Y; Zanichelli V; Wainberg MA
    J Virol; 2014 Feb; 88(3):1536-47. PubMed ID: 24227862
    [TBL] [Abstract][Full Text] [Related]  

  • 28. N348I in the connection domain of HIV-1 reverse transcriptase confers zidovudine and nevirapine resistance.
    Yap SH; Sheen CW; Fahey J; Zanin M; Tyssen D; Lima VD; Wynhoven B; Kuiper M; Sluis-Cremer N; Harrigan PR; Tachedjian G
    PLoS Med; 2007 Dec; 4(12):e335. PubMed ID: 18052601
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Plasma drug concentrations and virologic evaluations after stopping treatment with nonnucleoside reverse-transcriptase inhibitors in HIV type 1-infected children.
    Cressey TR; Green H; Khoo S; Treluyer JM; Compagnucci A; Saidi Y; Lallemant M; Gibb DM; Burger DM;
    Clin Infect Dis; 2008 May; 46(10):1601-8. PubMed ID: 18419497
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Distinct resistance patterns to etravirine and rilpivirine in viruses containing nonnucleoside reverse transcriptase inhibitor mutations at baseline.
    Asahchop EL; Wainberg MA; Oliveira M; Xu H; Brenner BG; Moisi D; Ibanescu IR; Tremblay C
    AIDS; 2013 Mar; 27(6):879-887. PubMed ID: 23262501
    [TBL] [Abstract][Full Text] [Related]  

  • 31. F18, a novel small-molecule nonnucleoside reverse transcriptase inhibitor, inhibits HIV-1 replication using distinct binding motifs as demonstrated by resistance selection and docking analysis.
    Lu X; Liu L; Zhang X; Lau TC; Tsui SK; Kang Y; Zheng P; Zheng B; Liu G; Chen Z
    Antimicrob Agents Chemother; 2012 Jan; 56(1):341-51. PubMed ID: 22037848
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Resistance profile and cross-resistance of HIV-1 among patients failing a non-nucleoside reverse transcriptase inhibitor-containing regimen.
    Delaugerre C; Rohban R; Simon A; Mouroux M; Tricot C; Agher R; Huraux JM; Katlama C; Calvez V
    J Med Virol; 2001 Nov; 65(3):445-8. PubMed ID: 11596076
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In vitro selection of HIV-1 CRF08_BC variants resistant to reverse transcriptase inhibitors.
    Wu H; Zhang XM; Zhang HJ; Zhang Q; Chen Z; Huang JD; Lee SS; Zheng BJ
    AIDS Res Hum Retroviruses; 2015 Feb; 31(2):260-70. PubMed ID: 25482475
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Novel patterns of nevirapine resistance-associated mutations of human immunodeficiency virus type 1 in treatment-naïve patients.
    Hachiya A; Gatanaga H; Kodama E; Ikeuchi M; Matsuoka M; Harada S; Mitsuya H; Kimura S; Oka S
    Virology; 2004 Oct; 327(2):215-24. PubMed ID: 15351209
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Low frequency nonnucleoside reverse-transcriptase inhibitor-resistant variants contribute to failure of efavirenz-containing regimens in treatment- experienced patients.
    Halvas EK; Wiegand A; Boltz VF; Kearney M; Nissley D; Wantman M; Hammer SM; Palmer S; Vaida F; Coffin JM; Mellors JW
    J Infect Dis; 2010 Mar; 201(5):672-80. PubMed ID: 20102272
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Etravirine and rilpivirine-specific mutations selected by efavirenz and nevirapine exposure in patients infected with HIV-1 non-B subtypes.
    Crawford KW
    AIDS; 2014 Sep; 28(15):2331-2. PubMed ID: 25050862
    [No Abstract]   [Full Text] [Related]  

  • 37. Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens.
    Bunupuradah T; Ananworanich J; Chetchotisakd P; Kantipong P; Jirajariyavej S; Sirivichayakul S; Munsakul W; Prasithsirikul W; Sungkanuparph S; Bowonwattanuwong C; Klinbuayaem V; Petoumenos K; Hirschel B; Bhakeecheep S; Ruxrungtham K
    Antivir Ther; 2011; 16(7):1113-21. PubMed ID: 22024527
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Amino acid mutation N348I in the connection subdomain of human immunodeficiency virus type 1 reverse transcriptase confers multiclass resistance to nucleoside and nonnucleoside reverse transcriptase inhibitors.
    Hachiya A; Kodama EN; Sarafianos SG; Schuckmann MM; Sakagami Y; Matsuoka M; Takiguchi M; Gatanaga H; Oka S
    J Virol; 2008 Apr; 82(7):3261-70. PubMed ID: 18216099
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Human immunodeficiency virus type 1 mutations selected in patients failing efavirenz combination therapy.
    Bacheler LT; Anton ED; Kudish P; Baker D; Bunville J; Krakowski K; Bolling L; Aujay M; Wang XV; Ellis D; Becker MF; Lasut AL; George HJ; Spalding DR; Hollis G; Abremski K
    Antimicrob Agents Chemother; 2000 Sep; 44(9):2475-84. PubMed ID: 10952598
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the Western Cape, South Africa.
    van Zyl GU; van der Merwe L; Claassen M; Zeier M; Preiser W
    J Med Virol; 2011 Oct; 83(10):1764-9. PubMed ID: 21837793
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.